EBITDA Margin % is calculated as EBITDA divided by its Revenue. Longduoduo Co's EBITDA for the
three
months ended in Mar. 2026 was $-0.17 Mil. Longduoduo Co's Revenue for the
three
months ended in Mar. 2026 was $0.19 Mil. Therefore, Longduoduo Co's EBITDA margin for the quarter that ended in Mar. 2026 was -90.91%.
Longduoduo Co (OTCPK:LDDD) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Longduoduo Co EBITDA Margin % Related Terms
Longduoduo Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Longduoduo Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LDDD vs AWHL, BIAF, MBAI: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, Longduoduo Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Longduoduo Co EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Longduoduo Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Longduoduo Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Longduoduo Co (LDDD) has a EBITDA Margin % of -90.91% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Longduoduo Co and its competitors.
Is Longduoduo Co's EBITDA Margin % too high?
Longduoduo Co's current EBITDA Margin % is -90.91%. Overall, Longduoduo Co has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Longduoduo Co's EBITDA Margin % compare to AWHL and BIAF?
Longduoduo Co's EBITDA Margin % of -90.91% can be compared against companies in the Medical Diagnostics & Research industry. The industry median EBITDA Margin % is 5.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.20, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Longduoduo Co and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Longduoduo Co's current EBITDA Margin % is -90.91%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Longduoduo Co stock overvalued right now?
Longduoduo Co (LDDD) has a current EBITDA Margin % of -90.91%. The stock's GF Value™ is $2.30, compared to a current price of $0.51 — trading 77.8% below its estimated fair value. The current EBITDA Margin % is -90.91%. Longduoduo Co's overall GF Score™ is 47/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Longduoduo Co (LDDD), the current EBITDA Margin % is -90.91% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Longduoduo Co (LDDD) Overvalued in 2026?
Based on GuruFocus' analysis, Longduoduo Co stock appears to be undervalued.
The current stock price of $0.51 is trading 77.8% below its estimated GF Value™ of $2.30.
Key valuation signals for LDDD:
EBITDA Margin %: -90.91%
GF Value™: $2.30 vs. price of $0.51 (77.8% below fair value)
No single metric tells the full story. See the LDDD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Longduoduo Co Ltd through its operating subsidiaries, is engaged in providing preventive healthcare solutions. It offers a wide range of comprehensive preventive healthcare services, including disease screening, healthcare treatments, healthcare products, and other related services. The company mainly focuses on the prevention of myocardial infarction, cerebral infarction, hemiplegia, and cardiovascular and cerebrovascular diseases. Its revenues are mainly generated from customers in the People's Republic of China.
47GF Score
Get the complete analysis for LDDD
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LDDD has been successfully added to your 
